Skip to main navigation

MoonLake

e: info@moonlaketx.com

About us
Science
Investor relations

Site - Main

About us
Science
Investor relations

e: info@moonlaketx.com

INVESTOR RELATIONS

Press Releases

Year

All News
2025
2024
2023
2022
2021

Nov 14 2023

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Read More +

Nov 5 2023

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

Read More +

Oct 15 2023

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

Read More +

Oct 11 2023

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

Read More +

Oct 4 2023

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

Read More +

Sep 6 2023

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

Read More +

Aug 10 2023

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

Read More +

Jul 25 2023

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

Read More +

Jun 28 2023

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

Read More +

Jun 26 2023

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

Read More +

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 16

Site - Investor Tools

Contact Us

MoonLake Immunotherapeutics AG Dorfstrasse 29, 6300 Zug, Schweiz/Switzerland

e: info@moonlaketx.com
media: media@moonlaketx.com
IR: ir@moonlaketx.com

Quick Links

Home
About us
Team
Science
Pipeline

Therapeutic focus
Investor relations
Careers
Privacy policy

© 2025 - MoonLake Immunotherapeutics

Privacy Policy